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The two main physiologic components of theresponse to a stressor are mediated by the hypotha-
lamus–pituitary–adrenocortical (HPA) axis and by the
locus coeruleus/norepinephrine (LC/NE) autonomic
nervous system. These responses result, respectively, in
increases in cortisol and catecholamine concentrations
in plasma.1 Excessive secretion of catecholamines can
occur because of neoplasia of the chromaﬃn cells of the
adrenal medulla, a so-called pheochromocytoma. In this
report, we describe a pony with an adrenal mass and
clinical signs suggestive of pheochromocytoma in which
measurements of catecholamines and their metabolites
were performed in vivo.
Case History
A 27-year-old Shetland pony mare weighing 205 kg
was presented for evaluation of acute colic poorly
responsive to metamizole (dipyrone). The mare had
been examined for laminitis 6 years previously and
received corrective shoeing regularly. Clinical signs con-
sistent with an active pheochromocytoma, such as
excessive sweating, tachycardia, or excitement had not
been observed before presentation.
Clinical Findings and Treatment
Upon presentation, the mare was lethargic, moder-
ately painful, tachycardic (80/min), tachypneic (80/min),
and rectal temperature was increased (39.7°C). The
mare showed diﬀuse hypertrichosis, pale mucous mem-
branes, and prolonged capillary reﬁll time. A rectal
examination, limited because of the size of the pony,
was unremarkable, and no reﬂux was obtained after
nasogastric intubation. A transcutaneous abdominal
ultrasound examination identiﬁed a large amount of
anechoic swirling free ﬂuid (Fig 1) and an approxi-
mately 15 9 20 9 20 cm heterogeneous mass cran-
ioventral to the left kidney (Fig 2). Diﬀerential
diagnoses for the abdominal mass included hematoma,
Fig 1. Transabdominal sonogram of the ventral abdomen using a
5-MHz convex probe in a cranio-caudal orientation showing large
amounts of echoic swirling free ﬂuid within the abdominal cavity
(depth of the display: 10 cm). Cranial is to the left.
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granuloma, or neoplasia originating from the adrenal
gland. No association with kidneys, lymph nodes,
spleen, intestine, or ovaries was visible, and these were
considered less likely origins. Hemoabdomen was con-
ﬁrmed by abdominocentesis that yielded red ﬂuid with
a total protein concentration of 60 g/L (reference inter-
val [RI], 0–20 g/L), a leukocyte count of 6.8 9 109/L
(RI, 0–5 9 109/L), a PCV of 34% (RI, 0%), a lactate
concentration of 14.6 mmol/L (RI, 0–2 mmol/L), and
an absence of platelets. Microscopic examination of
peritoneal ﬂuid disclosed no further abnormalities.
An initial CBC indicated a normal hematocrit (38%;
RI, 31–47%) and leukocytosis (12.3 9 109/L; RI, 5.3–
10.3 9 109/L) characterized by neutrophilia (8.1 9 109/
L; RI, 2.5–6 9 109/L) and monocytosis (0.9 9 109/L;
RI, 0.04–0.45 9 109/L). Abnormalities of the biochem-
istry proﬁle included severe hyperglycemia (384 mg/dL;
RI, 50.5–90.1 mg/dL), hyperlactatemia (16 mmol/L; RI,
0–2 mmol/L), hypoproteinemia (53.1 g/L; RI, 54–73 g/
L), hypoalbuminemia (18.6 g/L; RI, 32.2–39.9 g/L),
hyperlipidemia (triglycerides, 513 mg/dL; RI, 7.1–
33.6 mg/dL), and increases in BUN (22.4 mg/dL; RI,
9.3–18.6 mg/dL), CK (3328 IU/L; RI, 0–262 IU/L),
GGT (45 IU/L; RI, 11–26 IU/L), and GLDH (51 IU/
L; RI, 0–14 IU/L). An electrocardiogram (ECG)
showed unifocal ventricular tachycardia (Fig 3). Nonin-
vasive blood pressure (NIBP) monitored on several
occasions over the middle coccygeal artery using an
oscillometric monitora remained normal to mildly low.
Mean NIBP noncorrected to heart level was 62–
79 mmHg (reference, 88  14 mmHg).2 An echocardio-
gram performed when the pony was hemodynamically
normal several days after presentation to the hospital
disclosed no abnormalities. Anti-M€ullerian hormone
concentration (<0.01 ng/mL; RI, <2 ng/mL), measured
to rule out a granulosa cell tumor of the left ovary, also
was normal.
A secreting pheochromocytoma was suspected
because of the presence of mass cranial to the left
kidney, abdominal pain, hemoperitoneum, ventricular
tachycardia, severe hyperglycemia, and severe hyperlac-
tatemia. Initial treatment was aimed at hemodynamic
stabilization. Analgesia was provided because of persis-
tent signs of abdominal pain, and antibiotics were
administered to prevent septic peritonitis. Treatment
consisted of IV lactated Ringer’s solutionb (100 mL/kg/
d), metamizolec (45 mg/kg IV once), ﬂunixin meglu-
mined (1.1 mg/kg IV q12 h), and cefquinomee (1 mg/kg
Fig 2. Transabdominal sonogram of the left paralumbar fossa
using a 5-MHz convex ultrasound probe in a ventro-dorsal orien-
tation showing a large heterogenous mass cranioventral to the left
kidney (depth of the display: 24 cm). Dorsal is to the left.
Fig 3. ECG shows uniform ventricular tachycardia (ﬁrst 6 complexes) followed by sinus tachycardia. Lead I is a base-apex lead, and the
rest are nonconventional leads. Paper speed is 10 mm/s.
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IV q12 h). The ventricular tachycardia was treated with
magnesium sulfatef (12.5 g IV once over 25 minutes)
diluted in 1L of 0.9% NaClg and lidocaineh (1.3 mg/kg
IV over 15 minutes, followed by 0.05 mg/kg/min as a
constant rate infusion [CRI]). After the initial simulta-
neous administration of magnesium sulfate and
lidocaine, the rhythm changed to sinus tachycardia
(76–140/min). Propranololi (0.78 mg/kg PO once) was
given because of concern about the catecholamine eﬀect
on cardiac b-receptors and tranexamic acidj (5 mg/kg
IV once) was administered because of its antiﬁbri-
nolytic eﬀects. Protamine zinc insulink (0.1 IU/kg SQ
once) followed by an IV CRI of regular insulinl (0.01–
0.02 IU/kg/h) was given and blood glucose concentra-
tion returned to normal within 12 hours. The mare
remained lethargic and anorexic for 24 hours after the
initial treatment was started. After 3 days of supportive
treatment, the mare was in good general condition and
eating well. All treatments were stopped after 3 days of
hospitalization except for antibiotics and anti-inﬂam-
matory medications which were given for a total of
5 days.
Because of hypertrichosis and the history of chronic
laminitis, ACTH plasma concentration was measured
6 days after the acute episode of colic. The ACTH con-
centration was increased (104 pg/mL; RI, <28 pg/mL in
April),3 and therapy with pergolidem (2.5 lg/kg PO
q24h) was initiated.
Plasma and urine samples were collected simultane-
ously for the measurement of catecholamines and
metanephrines as previously described in dogs.4 Seven
days were allowed after the last dose of propranolol to
avoid false positives. Plasma from 3 hospitalized Shet-
land pony mares, aged 4–9 years, and urine from 1
pony were used as controls. Reasons for hospitalization
of the other ponies were colon impaction and gastric
ulcers, colon impaction and retained fetal membranes,
and uterine prolapse after parturition, respectively. The
mares were recovering from their diseases, and not
severely ill at the time of sampling. Creatinine concen-
trations were measured in plasma and nonacidiﬁed
urine, and urinalysis showed no abnormalities. Plasma
samples were collected in chilled heparin tubes, cen-
trifuged at 4°C, and stored at 80°C protected from
light. Ten milliliters of urine was placed in a plain sili-
cone-coated tube containing 280 lL of 20% HCl. Uri-
nary pH was measured using pH indicator stripes
(range of pH, 1-6), and HCl was added to achieve a pH
≤2 as needed for proper analysis. Samples were shipped
on dry ice and thawed immediately before analysis.
Plasma norepinephrine and epinephrine, plasma free
and total normetanephrine and metanephrine were
determined by high-performance liquid chromatography
(HPLC) tandem mass spectrometry.5–7 Urinary nore-
pinephrine, epinephrine, total normetanephrine, and
total metanephrine were quantiﬁed by HPLC with
amperometric detection as separate compounds.6,8 The
results are expressed as a ratio to urinary creatinine
concentrations. Samples were treated with sulfatase
(sul) and glucuronidase (glu) for the analysis of total
metanephrine and normetanephrine.
The pony with suspected pheochromocytoma had
higher plasma norepinephrine (11.92 nM vs. 0.61, 1.12,
and 1.15 nM), total normetanephrine (3.82 nM vs. 0.93,
1.02 and 0.84 nM [sul] and 19.24 nM vs. 3.94, 3.84 and
5.58 nM [glu]), and free normetanephrine (3.29 nM vs.
0.73, 0.72 and 0.66 nM) concentrations than the 3 con-
trol ponies. Furthermore, urinary norepinephrine
(69.2 nEq/mEq [nmol/mmol] vs. 3.1 nEq/mEq [nmol/
mmol]) and normetanephrine (76.2 nEq/mEq [nmol/
mmol] vs. 13.4 nEq/mEq [nmol/mmol] [sul] and
384.9 nEq/mEq [nmol/mmol] vs. 48.9 nEq/mEq [nmol/
mmol] [glu]) measurements were higher in the diseased
animal than in the control pony. All the results are
given in Table 1.
The pony was clinically normal after 1 week of hospi-
talization. An abdominal sonogram identiﬁed no free
abdominal ﬂuid at that time. The mass had decreased
in size (measuring 10 9 15 9 15 cm approximately)
and showed a hyperechoic outer layer with a hypoe-
choic ﬂuid-ﬁlled area interpreted as a reorganizing
hematoma. Transrectal ultrasound examination of the
left adrenal gland was considered but not performed
because of concerns about manipulation leading to an
adrenergic crisis. Because of the lack of medical therapy
available for treatment of pheochromocytoma, surgical
removal of the adrenal mass was planned and advanced
imaging scheduled to prepare for the surgical procedure.
To decrease the potential risk of catecholamine release
during general anesthesia, phenoxybenzaminen (dosing
protocol: 0.2 mg/kg PO q24h twice, then 0.3 mg/kg PO
q12h for 2 days, then 0.4 mg/kg PO q12h for 3 days,
then 0.5 mg/kg PO q12h for 8 days) was administered.
During the treatment, heart rate remained normal (40–
44/min) and mean noncorrected NIBP decreased ini-
tially (50 mmHg) and then stabilized at approximately
66 mmHg. No other adverse eﬀects were observed.
Two weeks later, the pony was presented again for
further diagnostic investigations under general anesthe-
sia. A balanced electrolyte solution (2 mL/kg/h) was
given for 12 hours before anesthesia, and phenoxyben-
zamine therapy was discontinued the evening before the
intervention.
The pony was premedicated with dexmedetomidineo
(3.5 lg/kg IV) and levo-methadonep (0.05 mg/kg IV),
and anesthesia was induced with diazepamq (0.1 mg/kg
IV), propofolr (2 mg/kg IV), and thiopentals (0.25 mg/
kg IV). Anesthesia was maintained with isoﬂuranet in
100% oxygen and lidocaineu (1.8 mg/kg/h IV). Mean
arterial pressure >60 mmHg, assessed by NIBP mea-
surement at the base of the tail, was achieved using lac-
tated Ringer’s solutionb (10 mL/kg/h), dobutaminev
(0.2–4 lg/kg/min), and norepinephrinew (0.1–0.5 lg/kg/
min). Heart rate ranged between 36 and 51/min. The
mare recovered without incident.
Computed tomography (CT) of the abdomen was
performed using a 16-slice spiral computed tomography
scanner. Images were acquired with 120 kV and 270
mAs. Postcontrast images were acquired after adminis-
tration of 80 mL nonionic iodinated (300 mg/mL) con-
trast medium. A space-occupying lesion was identiﬁed
craniomedially to the left kidney, with a cavitary medial
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part of 7 cm in diameter with a hypodense center
(pre- and postcontrast approximately 30 Hounsﬁeld
Units [HU]) and a contrast-enhancing peripheral ring
(precontrast, 33 HU; postcontrast, 97 HU). The latero-
caudal part of the lesion was slightly heterogenous and
ill-deﬁned with a diameter of 6 cm. On the right side, a
homogenous, soft tissue-attenuating and mildly con-
trast-enhancing lesion (precontrast, 63 HU; postcon-
trast, 97 HU) with a diameter of approximately 6 cm
was identiﬁed craniomedially to the right kidney
(Fig 4). Both mass lesions were suspected to be adrenal
glands. Although exact sizes for adrenal glands of
horses on CT are not reported in the veterinary
literature, left adrenal glands have been measured using
transrectal ultrasound and the mean diameter (SD)
did not exceed 0.89  0.18 cm.9 Furthermore, adrenal
glands are anatomically described as small, ﬂattened
organs with a size of approximately 9–10 cm long,
3–4 cm wide, and approximately 1.5 cm or more in
thickness.10 Assuming that adrenal glands usually have
about the same size and would be expected to be even
smaller in a pony, we assumed that both were enlarged
in the patient. The cavitary lesion of the left adrenal
mass was suspected to be a hematoma in regression or
a cystic pheochromocytoma.11 Diﬀerential diagnosis for
the enlarged right adrenal gland included adrenal hyper-
plasia, adenoma, adenocarcinoma, or pheochromocy-
toma. Because of the presence of bilateral masses,
surgery was not considered and the pony was dis-
charged with pergolide as the only treatment. The
owner reported that the mare had not had signs of dis-
ease during the 12 months after discharge.
To the best of our knowledge, this is the ﬁrst report
of an antemortem diagnosis of pheochromocytoma in
an equid using analysis of plasma and urinary cate-
cholamines and metabolites. Diagnosis and manage-
ment followed the standard of care in small animals
and humans with suspected pheochromocytomas, and
such an approach has been mentioned in previous
reports in horses.12 The biochemical test of choice for
pheochromocytomas in human medicine is measurement
of plasma or 24-hour urinary fractioned metanephrines
in addition to CT or magnetic resonance imaging.13
Collection of urine during 24 hours is impractical in
horses, and determination of plasma and urinary
metanephrine and normetanephrine is considered
appropriate for the diﬀerentiation of dogs with
pheochromocytomas from those with hypercortisolism,
Fig 4. Transverse postcontrast CT image of the abdomen at the
level of the cranial pole of the left kidney (LK), which is located
medially to the spleen. The left adrenal gland (LA) is soft tissue
attenuating at its lateral aspect with a cavitary mediodorsal part
(white arrows). Medially to the right kidney (RK), the soft tissue
attenuating right adrenal gland (RA) is visible.
Table 1. Results of plasma (P-) catecholamines and plasma total and free metanephrines and urinary (U-) cate-
cholamines, metanephrines to creatinine ratios, vanillyl mandelic acid, and homovanillic acid to creatinine ratios in a
pony with suspected pheochromocytoma (PC) and controls (C1, C2, C3).
Parameter PC C1 C2 C3
P-dopamine (nmol/L) 0.18 0.10 0.04 0.10
P-epinephrine (nmol/L) 0.15 1.03 1.13 0.46
P-norepinephrine (nmol/L) 11.62 0.61 1.12 1.15
P-total metanephrine (nmol/L) [sulfatase-treated] 0.16 0.97 0.42 0.31
P-total metanephrine (nmol/L) [glucuronidase-treated] 1.17 5.94 2.41 2.12
P-free metanephrine (nmol/L) 0.16 0.94 0.26 0.25
P-total normetanephrine (nmol/L) [sulfatase-treated] 3.82 0.93 1.02 0.84
P-total normetanephrine (nmol/L) [glucuronidase-treated] 19.24 3.94 3.84 5.58
P-free normetanephrine (nmol/L) 3.29 0.73 0.72 0.66
P-total methoxytyramine (nmol/L) [sulfatase-treated] 0.01 0.05 0.08 0.02
P-total methoxytyramine (nmol/L) [glucuronidase-treated] 7.32 7.77 7.15 6.08
P-free methoxytyramine (nmol/L) 0.02 0.10 0.10 0.06
U-dopamine: creatinine (nmol/mmol) 20.9 11.6
U-epinephrine: creatinine (nmol/mmol) 1.6 2.1
U-norepinephrine: creatinine (nmol/mmol) 69.2 3.1
U-metanephrine: creatinine (nmol/mmol) [sulfatase-treated] 4 12.2
U-metanephrine: creatinine (nmol/mmol) [glucuronidase-treated] 23.1 63.3
U-normetanephrine: creatinine (nmol/mmol) [sulfatase-treated] 76.2 13.4
U-normetanephrine: creatinine (nmol/mmol) [glucuronidase-treated] 384.9 48.9
U-vanillyl mandelic acid: creatinine (lmol/mmol) 1.82 0
U-homovanillic acid: creatinine (lmol/mmol) 10.4 1.82
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nonadrenal diseases, and healthy controls.4 Pheochro-
mocytoma is considered highly probable in humans
with plasma concentrations of normetanephrines and
metanephrines >4 times the reference concentration.14
In the case presented here, these criteria were met for
plasma norepinephrine and normetanephrines, urinary
norepinephrine, and normetanephrine-to-creatinine
ratio. Norepinephrine seemed to be the most markedly
increased catecholamine, which agrees with reports in
aﬀected dogs.4
Extrapolation of conclusions from other species
should be performed with caution, and results of total
metanephrine and normetanephrine show a remarkable
diﬀerence between horses and other species because cate-
cholamine metabolites are mostly glucuroconjugated
and not sulfoconjugated.1,4 Methoxythyramine, a cate-
cholamine metabolite, also is glucuroconjugated in
horses.15 We presented the individual control results
rather than an average because only 3 animals were used
for comparison. Preliminary data can be used to deﬁne
the sample size needed to establish a reference range.
Data obtained from an appropriate sized control popu-
lation should be checked for normality, and reference
ranges established based on the 95% conﬁdence interval.
A larger number of horses with pheochromocytomas
will need to be compared to healthy controls to conﬁrm
that patterns described in small animals and humans are
followed by horses with pheochromocytomas. It is a lim-
itation of the diagnosis in this case that the comparison
was made with a small group of hospitalized ponies and
that the absolute concentrations and ratios were some-
what lower than those commonly described in dogs and
people with pheochromocytomas.4,14 Nevertheless, the
large diﬀerences between the case and controls support
the diagnosis in these species. Diﬀerences in laboratory
methods complicate direct comparison of the results
among studies, and reliable reference ranges are not
available for horses.
Horses with laminitis or colic have been shown to
have increased serum norepinephrine concentrations
compared to controls.16 This might have been a con-
founding factor; however, signs of laminitis or colic
were not present at the time of sampling. It is a major
limitation that the diagnosis of pheochromocytoma was
not conﬁrmed histopathologically and assessment using
radionuclide imaging modalities was not performed.
Pheochromocytomas in horses can be suspected clin-
ically and conﬁrmed postmortem or during exploratory
laparotomy.11,17,18 Pheochromocytomas often are
asymptomatic and often are found incidentally during
necropsy in horses. If clinical signs are present, colic is
the most common presenting complaint,19 and
hemoabdomen,20,21 arrhythmias, tachycardia,12,17 severe
hyperglycemia, and hyperlactemia are commonly
reported in horses with pheochromocytomas.19 Hyper-
glycemia previously has been described in humans with
pheochromocytomas because of increased glycogenoly-
sis and inhibition of insulin secretion caused by
increased plasma concentrations of catecholamines.22
Hyperglycemia could have been secondary to pituitary
pars intermedia dysfunction (PPID) in the pony we
report here. Nevertheless, the pony responded to
insulin therapy and hyperglycemia did not recur.
Hyperlactemia has been associated with vasoconstric-
tive ischemia or hemorrhagic shock in cases of
pheochromocytoma.19
Pheochromocytomas have been described in large
animals as single lesions or as part of a multiple endo-
crine-like syndrome.23,24 Other endocrine tissues aﬀected
by hyperplasia or neoplasia in multiple endocrine-like
syndrome include the thyroid gland, parathyroidal C
cells, and the pituitary pars intermedia. Concomitant
adrenal hyperplasia and bilateral pheochromocytomas
have been described,19 and 14/32 and 2/32 of horses
diagnosed with PPID reportedly had diﬀuse adrenocor-
tical hyperplasia and pheochromocytoma, respectively,
in a retrospective study.25
Adrenergic crisis has been described in humans with
pheochromocytomas during induction of anesthesia
and intubation.26 Phenoxybenzamine, an adrenergic
a-blocker, is the drug of choice to prevent this
complication,27 and the protocol used here was adapted
from recommendations for humans28 and pharmacolog-
ical and anecdotal reports in horses.29,30 Administration
of b-blockers to individuals with pheochromocytomas
without prior administration of adrenergic a-blockers
has been discouraged because of the risk of unopposed
a-adrenergic receptor stimulation causing a hypertensive
crisis.31,32 Administration of phenoxybenzamine before
propranolol would have been indicated in this case.
Surgical removal of the tumor is indicated for
humans and small animals with functional and symp-
tomatic pheochromocytomas. Laparoscopic removal is
the preferred technique, but laparotomy also is
described.32 To the best of our knowledge, surgical
removal of a pheochromocytoma in a horse has not
been reported, although the surgical technique for
adrenalectomy is described in normal horses.33,34
Because of the size and location of the mass, an open
approach via the left ﬂank with the pony in right lateral
recumbency and under general anesthesia was planned.
Dopamine receptors are expressed in human adrenal
tumors including pheochromocytomas and D2 receptors
have inhibitory eﬀects on norepinephrine secretion.35
The hypothesis of a possible eﬀect of dopamine agonists
in the control of hormonal hypersecretion associated
with adrenal tumors has been formulated but not
proven.36 Pergolide, a dopamine agonist, was adminis-
tered to the pony described here for the treatment of
PPID. The eﬀects of pergolide on pheochromocytomas
in horses are speculative, but interestingly, there was
remission of clinical signs during treatment.
In conclusion, measurement of catecholamines and
their metabolites in plasma and urine can be used in the
diagnosis of suspected pheochromocytoma. Further
information regarding the concentrations of cate-
cholamines and their metabolites in healthy and ill
horses and in horses with pheochromocytomas would
help clinicians in managing horses in which this tumor
is suspected.
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Footnotes
a Cardell Veterinary Monitor 9402, CAS Medical Systems, Brand-
ford, CT, USA
b Ringer-Lactat “Bichsel” ohne/sans Glucose, Grosse Apotheke
Dr. G. Bichsel AG, Interlaken, Switzerland
c Vetalgin, MSD Animal Health GmbH, Luzern, Switzerland
d Fluniximin, Dr. E. Graeub AG, Bern, Switzerland
e Cobactan IV 4.5%, MSD Animal Health GmbH, Luzern,
Switzerland
f Magnesiumsulfat “Bichsel” 10%, Grosse Apotheke Dr. G. Bich-
sel AG, Interlaken, Switzerland
g Natrium chloratum “Bichsel,” Grosse Apotheke Dr. G. Bichsel
AG, Interlaken, Switzerland
h Lidocain 2% Streuli, Streuli Pharma AG, Uznach, Switzerland
i Propranolol retard, Helvepharm AG, Frauenfeld, Switzerland
j Cyclocapron-Injektionsl€osung, Pharmacia GmbH/ Pﬁzer
GmbH, Berlin, Germany
k Caninsulin, MSD Animal Health GmbH, Luzern, Switzerland
l Novorapid, Novo Nordisk Pharma AG, K€usnacht, Switzerland
m Prascend, Boehringer Ingelheim (Schweiz) GmbH, Basel,
Switzerland
n Phenoxybenzamin HCl BP, Christoﬀel-Apotheke, Bern, Switzer-
land
o Dexdomitor, Provet AG, Lyssach, Switzerland
p L-Polamivet, MSD Animal Health GmbH, Luzern, Switzerland
q Valium, Roche Pharma (Schweiz) AG, Reinach, Switzerland
r Propofol 1% MCT, Fresenius Kabi, Oberdorf, Switzerland
s Pentothal, Ospedalia AG, H€unenberg, Switzerland
t AttaneTM, Provet AG, Lyssach, Switzerland
u Lidocain 2% Streuli, Streuli Pharma AG, Uznach, Switzerland
v Dobutrex, Teva Pharma AG, Basel, Switzerland
w Noradrenalin Sintetica, Sintetica S.A., Mendrisio, Switzerland
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